Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Kathy, Wolski"'
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Autor:
Ulf Landmesser, Børge G Nordestgaard, Leslie Cho, Niels Eske Bruun, Sotirios Tsimikas, Stephen J Nicholls, A Michael Lincoff, Steven E Nissen, Eran Leitersdorf, Kathy Wolski, John Kastelein, Michael Blaha, Ryuichi Morishita, Junhao Liu, Brian Manning, Plamen Kozlovski, Anastasia Lesogor, Tom Thuren, Taro Shibasaki, Florin Matei, Fábio Serra Silveira, Andreas Meunch, Aysha Bada, Vinod Vijan
Publikováno v:
Open Heart, Vol 9, Iss 2 (2022)
Objective Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global
Externí odkaz:
https://doaj.org/article/69a4df2faa554bac9af4585ef3cef707
Autor:
Cameron T. Lambert, MD, Divyang Patel, MD, Joseph M. Bumgarner, MD, Mohamed Kanj, MD, Daniel Cantillon, MD, FHRS, Walid Saliba, MD, Ayman Hussein, MD, FHRS, Bryan Baranowski, MD, Thomas Dresing, MD, Mina K. Chung, MD, FHRS, John Rickard, MD, MPH, Niraj Varma, MD, PhD, Thomas Callahan, MD, FHRS, David Martin, MD, Patrick Tchou, MD, FHRS, Mandeep Bhargava, MD, Kathy Wolski, MS, Oussama Wazni, MD, FHRS, Khaldoun G. Tarakji, MD, MPH, FHRS
Publikováno v:
Cardiovascular Digital Health Journal, Vol 2, Iss 2, Pp 92-100 (2021)
Background: Direct-to-consumer devices allow patients to record electrocardiograms (ECG) and detect atrial fibrillation (AF). Clinical adoption of these devices has been limited owing to the lack of efficient workflow. Objective: To assess a new care
Externí odkaz:
https://doaj.org/article/afddd06cda1c4b1abee55b09d752a9c9
Autor:
Milind Y. Desai, Anjali Owens, Jeffrey B. Geske, Kathy Wolski, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C. Cremer, Srihari S. Naidu, Nicholas G. Smedira, Hartzell Schaff, Ellen McErlean, Christina Sewell, Aarthi Balasubramanyam, Kathy Lampl, Amy J. Sehnert, Steven E. Nissen
Publikováno v:
Circulation. 147:850-863
Background: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aee0a8c91b0b870ab07e220056b6c2ae
https://doi.org/10.1161/circulationaha.122.062534
https://doi.org/10.1161/circulationaha.122.062534
Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound
Autor:
Chetan P. Huded, Nishant P. Shah, Rishi Puri, Stephen J. Nicholls, Kathy Wolski, Steven E. Nissen, Leslie Cho
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 23 (2020)
Background Lp(a) (lipoprotein (a)) is a risk factor for cardiovascular events, but the mechanism of increased risk is uncertain. This study evaluated the relationship between Lp(a) and coronary atheroma volume by intravascular ultrasound. Methods and
Externí odkaz:
https://doaj.org/article/fae628c9742042a68b700ec6e6bfc21d
Autor:
Andrew Xanthopoulos, Konstantinos Tryposkiadis, Filippos Triposkiadis, Kiyotaka Fukamachi, Edward G. Soltesz, James B. Young, Kathy Wolski, Eugene H. Blackstone, Randall C. Starling
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 14 (2020)
Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate
Externí odkaz:
https://doaj.org/article/cd0e9c216a304f2784340e353f93088b
Autor:
Stephen J, Nicholls, Yu, Kataoka, Steven E, Nissen, Francesco, Prati, Stephan, Windecker, Rishi, Puri, Thomas, Hucko, Daniel, Aradi, Jean-Paul R, Herrman, Renicus S, Hermanides, Bei, Wang, Huei, Wang, Julie, Butters, Giuseppe Di, Giovanni, Stephen, Jones, Gianluca, Pompili, Kathy, Wolski, Peter J, Psaltis
Publikováno v:
JACC: Cardiovascular Imaging. 16:130-132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb70ca913aa03c292db307ce57637a99
https://doi.org/10.1016/j.jcmg.2022.07.020
https://doi.org/10.1016/j.jcmg.2022.07.020
Autor:
Amit Anand, Sanjay J. Mathew, Gerard Sanacora, James W. Murrough, Fernando S. Goes, Murat Altinay, Amy S. Aloysi, Ali A. Asghar-Ali, Brian S. Barnett, Lee C. Chang, Katherine A. Collins, Sara Costi, Sidra Iqbal, Manish K. Jha, Kamini Krishnan, Donald A. Malone, Sina Nikayin, Steven E. Nissen, Robert B. Ostroff, Irving M. Reti, Samuel T. Wilkinson, Kathy Wolski, Bo Hu
Publikováno v:
New England Journal of Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1004300a18618ff4d944d59b16804fb1
https://doi.org/10.1056/nejmoa2302399
https://doi.org/10.1056/nejmoa2302399
Autor:
Paul C. Cremer, Jeffrey B. Geske, Anjali Owens, Wael A. Jaber, Serge C. Harb, Sara Saberi, Andrew Wang, Mark Sherrid, Srihari S. Naidu, Hartzell Schaff, Nicholas G. Smedira, Qiuqing Wang, Kathy Wolski, Kathy L. Lampl, Amy J. Sehnert, Steven E. Nissen, Milind Y. Desai
Publikováno v:
Circulation: Cardiovascular Imaging. 15
Background: In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic cardiomy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b2fd5e22bed784a538d8dfaeb35eac
https://doi.org/10.1161/circimaging.122.014986
https://doi.org/10.1161/circimaging.122.014986
Autor:
Steven E. Nissen, Michael W. Kattan, Stacy A Brethauer, Philip R. Schauer, Ali Aminian, Kathy Wolski, Alexander Zajichek, Chao Tu, Rickesha Wilson
Publikováno v:
Diabetes Care. 44:2552-2563
OBJECTIVE To determine which one of the two most common metabolic surgical procedures is associated with greater reduction in risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and obesity. RESEARCH DE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465daa793808bb737945c7a63b775e38
https://doi.org/10.2337/dc20-3023
https://doi.org/10.2337/dc20-3023
Autor:
Kathy Wolski, Hartzell V. Schaff, David Zhang, Jeffrey B. Geske, Ellen McErlean, Srihari S. Naidu, Anjali T. Owens, Lampl Kathy L, Nicholas G. Smedira, Christina Sewell, Jay M. Edelberg, Milind Y. Desai, Amy J. Sehnert, Steven E. Nissen
Publikováno v:
American Heart Journal. 239:80-89
Background Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder which frequently leads to symptoms such as dyspnea and exercise intolerance, often due to severe dynamic left ventricular outflow tract obstruction (LVOTO). Current guideli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730fd901d2b8cd73da2ef16bdd9e4907
https://doi.org/10.1016/j.ahj.2021.05.007
https://doi.org/10.1016/j.ahj.2021.05.007